Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22

References

• Bahadur RKC, Chandrashekaran V, Cheng B, et al. (2014). Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharmaceut 11:1897–905
   PubMed Web of Science ®Google Scholar
• Bildstein L, Dubernet C, Couvreur P. (2011). Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 63:3–23
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–26
   PubMed Web of Science ®Google Scholar
• Chen H, Gao J, Lu Y, et al. (2008). Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release 128:209–16
   PubMed Web of Science ®Google Scholar
• Cırpanlı Y, Allard E, Passirani C, et al. (2011). Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 403:201–6
   PubMed Web of Science ®Google Scholar
• Çirpanli Y, Bilensoy E, Dogan AL, Çalis S. (2009). Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm 73:82–9
   PubMed Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Lange N, et al. (2010). Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144:324–31
   PubMed Web of Science ®Google Scholar
• Fan HL, Huang J, Li YP, et al. (2010). Fabrication of reduction degradable micelle based on disulfide-linked graft copolymer-camptothecin conjugate for enhancing solubility and stability of camptothecin. Polymer 515:107–14
   Google Scholar
• Fay F, McLaughlin KM, Small DM, et al. (2011). Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 32: 8645–53
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–917
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–61
   PubMed Web of Science ®Google Scholar
• Guo Q, Luo P, Luo Y, et al. (2012). Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloid Surface B 100:138–45
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, Ostman A. (2004). High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4:806–13
   PubMed Web of Science ®Google Scholar
• Hong M, Zhu S, Jiang Y, et al. (2010). Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferring-PEG-nanoparticles. J Control Release 141:22–9
   PubMed Web of Science ®Google Scholar
• Jia LJ, Zhang DR, Li ZY, et al. (2010). Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B 80:213–18
   PubMed Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, et al. (2007). Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–26
   PubMed Web of Science ®Google Scholar
• Kunii R, Onishi H, Machida Y. (2007). Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Sci 67:9–17
   Google Scholar
• Lei TJ, Srinivasan S, Tang Y, et al. (2011). Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomed Nanotechnol 7:324–32
   PubMed Web of Science ®Google Scholar
• Li ZL, Xiong XY, Li YP, et al. (2010). Synthesis and self-assembling behaviors of biotinylated pluronic/poly(lactic acid) biocompatible block copolymers in aqueous solutions. J Appl Polym Sci 115:1573–80
   Web of Science ®Google Scholar
• Liang FY, Zhang SH, Pan Y, et al. (1999). Use of monoclonal antibody norcantharidin conjugate in experimental targeting therapy of tumor. Chin J Zoology 34:18–22
   Google Scholar
• Luo ZL, Jiang JW. (2012). pH-sensitive drug loading/releasing in amphiphilic copolymer PAE-PEG: Integrating molecular dynamics and dissipative particle dynamics simulations. J Control Release 162:185–93
   PubMed Web of Science ®Google Scholar
• McCarron PA, Marouf WM, Quinn DJ, et al. (2008). Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjugate Chem 19:1561–9
   PubMed Web of Science ®Google Scholar
• Modi S, Xiang TX, Anderson BD. (2012). Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. J Control Release 162:330–9
   PubMed Web of Science ®Google Scholar
• Okamura K, Koike H, Sekine Y, et al. (2009). Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol 33:137–41
   PubMed Web of Science ®Google Scholar
• Paranjpe PV, Chen Y, Kholodovych V, et al. (2004). Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J Control Release 100:275–92
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007). Drug targeting to the brain. Pharm Res 24:1733–44
   PubMed Web of Science ®Google Scholar
• Pulkkinen M, Pikkarainen J, Wirth T, et al. (2008). Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur J Pharm Biopharm 70:66–74
   PubMed Web of Science ®Google Scholar
• Shenderova A, Burke TG, Schwendeman SP. (1999). The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 16:241–8
   PubMed Web of Science ®Google Scholar
• Shukla R, Thomas TP, Peters JL, et al. (2006). HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjugate Chem 17:1109–15
   PubMed Web of Science ®Google Scholar
• Stauber RH, Mann W, Knauer SK. (2007). Nuclear and cytoplasmic Survivin: molecular mechanism, prognostic, and the therapeutic potential. Cancer Res 67:5999–6002
   PubMed Web of Science ®Google Scholar
• Sun B, Ranganathan B, Feng SS. (2008). Multifunctional poly(D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29:475–86
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Pastero L, Serpe L, et al. (2010). Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 74:193–201
   PubMed Web of Science ®Google Scholar
• Topcu Z. (2001). DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Therap 26:405–16
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Simanek EE. (2010). Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 7:307–49
   PubMed Web of Science ®Google Scholar
• Xiong XY, Guo L, Gong YC, et al. (2012). In vitro & in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction. Eur J Pharm Sci 46:537–44
   PubMed Web of Science ®Google Scholar
• Yang AS, Yang L, Liu W, et al. (2007). Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm 331:123–32
   PubMed Web of Science ®Google Scholar